Numerous reports have indicated that the plasma concentration of endogenously produced inhibitors of nitric oxide synthase are elevated in human disease states. In this review we discuss recent advances in our understanding of the enzymes responsible for the synthesis of these inhibitors.
Aisaka K, Gross SS, Griffith OW, Levi R.NG-methylarginine, an inhibitor of endothelium-derived nitric oxide synthesis, is a potent pressor agent in the guinea pig: does nitric oxide regulate blood pressure in vivo?Biochem Biophys Res Commun1989; 160: 881-886.
5.
Rees DD, Palmer RM, Hodson HF, Moncada S.A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol1989; 96: 418-424.
6.
Vallance P, Collier J, Moncada S.Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet1989; ii: 997-1000.
7.
Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P.Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res1994; 28: 34-39.
8.
Baldwin GS, Carnegie PR.Isolation and partial characterization of methylated arginines from the encephalitogenic basic protein of myelin. Biochem J1971; 123: 69-74.
9.
Wang S, Wright G, Geng W, Wright GL.Retinol influences contractile function and exerts an anti-proliferative effect on vascular smooth muscle cells through an endothelium-dependent mechanism. Pflugers Arch1997; 434: 669-677.
10.
Lischwe MA, Ochs RL, Reddy Ret al.Purification and partial characterisation of a nucleolar scleroderma antigen rich in NG, Ng-dimethylarginine. J Biol Chem1985; 260: 14304-14310.
11.
Lischwe MA, Cook RG, Ahn YSet al.Clustering of glycine and Ng, NG-dimethylarginine in nucleolar protein C23. Biochemistry1985; 22: 6025-6028.
12.
Paik WK, Kim S.Protein methylase I. Purification and properties of the enzyme. J Biol Chem1968; 243: 2108-2114.
13.
Ghosh SK, Paik WK, Kim S.Purification and molecular identification of two protein methylases I from calf brain. Myelin basic protein- and histone-specific enzyme. J Biol Chem1988; 263: 19024-19033.
14.
Najbauer J, Johnson BA, Young AL, Aswad DW.Peptides with sequences similar to glycine, arginine-rich motifs in proteins interacting with RNA are efficiently recognised by methyltrasferases modifying arginine in numerous proteins. J Biol Chem1993; 268: 10501-10509.
15.
Rajpurohit R, Paik WK, Kim S.Enzymatic methylation of heterogenous nuclear ribonucleoprotein in isolated liver nuclei. Biochim Biophys Acta1992; 1122: 183-188.
16.
Lin WJ, Gary JD, Yang MC, Clarke S, Herschman HR.The mammalian immediate-early TIS21 protein and the leukemia-associated BTG1 protein interact with a protein-arginine N-methyltransferase. J Biol Chem1996; 271: 15034-15044.
17.
Katsanis N, Yaspo ML, Fisher EM.Identification and mapping of a novel human gene, HRMT1L1, homologous to the rat protein arginine N-methyltransferase 1 (PRMT1) gene. Mamm Genome1997; 8: 526-529.
18.
Tang J, Gary JD, Clarke S, Herschman HR.PRMT 3, a type I protein arginine N-methyltransferase that differs from PRMT1 in its oligomerization, subcellular localization, substrate specificity, and regulation. J Biol Chem1998; 273: 16935-16945.
19.
Chen D, Ma H, Hong Het al.Regulation of transcription by a protein methyltransferase. Science1999; 284: 2174-2177.
20.
Branscombe TL, Frankel A, Lee JHet al.PRMT5 (Janus kinase-binding protein 1) catalyzes the formation of symmetric dimethylarginine residues in proteins. J Biol Chem2001; 276: 32971-32976.
21.
Frankel A, Yadav N, Lee J, Branscombe TL, Clarke S, Bedford MT.The novel human protein arginine N-methyltransferase PRMT6 is a nuclear enzyme displaying unique substrate specificity. J Biol Chem2002; 277: 3537-3543.
22.
Miranda TB, Miranda M, Frankel A, Clarke S.PRMT7 is a member of the protein arginine methyltransferase family with a distinct substrate specificity. J Biol Chem2004; 279: 22902-22907.
23.
Wang H, Huang ZQ, Xia Let al.Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor. Science2001; 293: 853-857.
24.
Yadav N, Lee J, Kim Jet al.Specific protein methylation defects and gene expression perturbations in coactivator-associated arginine methyltransferase 1-deficient mice. Proc Natl Acad Sci USA2003; 100: 6464-6468.
25.
Gary JD, Clarke S.RNA and protein interactions modulated by protein arginine methylation. Prog Nucleic Acid Res Mol Biol1998; 61: 65-131.
26.
Belyanskaya LL, Gehrig PM, Gehring H.Exposure on cell surface and extensive arginine methylation of ewing sarcoma (EWS) protein. J Biol Chem2001; 276: 18681-18687.
27.
Abramovich C, Yakobson B, Chebath J, Revel M.A protein-arginine methyltransferase binds to the intracytoplasmic domain of the IFNAR1 chain in the type I interferon receptor. EMBO J1997; 16: 260-266.
28.
Mowen KA, Tang J, Zhu Wet al.Arginine methylation of STAT1 modulates IFNalpha/beta-induced transcription. Cell2001; 104: 731-741.
29.
Koh SS, Chen D, Lee YH, Stallcup MR.Synergistic enhancement of nuclear receptor function by p160 coactivators and two coactivators with protein methyltransferase activities. J Biol Chem2001; 276: 1089-1098.
30.
Lee J, Bedford MT.PABP1 identified as an arginine methyltransferase substrate using high-density protein arrays. EMBO Rep2002; 3: 268-273.
31.
Chen D, Huang SM, Stallcup MR.Synergistic, p160 coactivator-dependent enhancement of estrogen receptor function by CARM1 and p300. J Biol Chem2000; 275: 40810-40816.
32.
Li H, Park S, Kilburn Bet al.Lipopolysaccharide-induced methylation of HuR, an mRNA-stabilizing protein, by CARM1. Coactivator-associated arginine methyltransferase. J Biol Chem2002; 277: 44623-44630.
33.
Pawlak MR, Scherer CA, Chen J, Roshon MJ, Ruley HE.Arginine N-methyltransferase 1 is required for early postim-plantation mouse development, but cells deficient in the enzyme are viable. Mol Cell Biol2000; 20: 4859-4869.
34.
Chen SL, Loffler KA, Chen D, Stallcup MR, Muscat GE.The coactivator-associated arginine methyltransferase is necessary for muscle differentiation: CARM1 coactivates myocyte enhancer factor-2. J Biol Chem2002; 277: 4324-4333.
Wang Y, Wysocka J, Sayegh Jet al.Human PAD4 regulates histone arginine methylation levels via demethylimination. Science2004; 306: 279-283.
37.
Kakimoto Y, Akazawa S.Isolation and identification of N- G, N-G- and N-G, N′-G-dimethy-L-arginine, N-epsilon-mono-, di-, and trimethyllysine, and glucosylgalactosyl- and galactosyl-delta-hydroxylysine from human urine. J Biol Chem1970; 245: 5751-5758.
38.
Vallance P, Leone A, Calver A, Collier J, Moncada S.Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet1992; 339: 572-575.
39.
MacAllister RJ, Vallance P.Nitric oxide in essential and renal hypertension. J Am Soc Nephrol1994; 5: 1057-1065.
40.
Olken NM, Marletta MA.NG-methyl-L-arginine functions as an alternative substrate and mechanism based inhibitor of nitric oxide synthase. Biochemistry1993; 32: 9677-9685.
41.
Vallance P, Leone A, Calver Aet al.Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet1992; 339: 572-575.
42.
Goonasekera CD, Rees DD, Woolard Pet al.Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens1997; 15: 901-909.
43.
Chen BM, Xia LW, Zhao RQ.Determination of N(G), N(G)-dimethylarginine in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl1997; 692: 467-471.
44.
Holden DP, Fickling SA, Whitley GSet al.Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia. Am J Obstet Gynecol1998; 178: 551-556.
45.
Matsuoka H, Itoh S, Kimoto Met al.Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension1997; 29(1 Pt 2): 242-247.
46.
Gorenflo M, Zheng C, Werle Eet al.Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol2001; 37: 489-492.
47.
Miyazaki H, Matsuoka H, Cooke JPet al.Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation1999; 99: 1141-1146.
48.
Boger RH, Bode-Boger SM, Kienke Set al.Dietary L-arginine decreases myointimal cell proliferation and vascular monocyte accumulation in cholesterol-fed rabbits. Atherosclerosis1998; 136: 67-77.
49.
Boger RH, Bode-Boger SM, Szuba Aet al.Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation1998; 98: 1842-1847.
50.
Bode-Boger SM, Boger RH, Kienke Set al.Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun1996; 219: 598-603.
51.
Herlitz H, Petersson A, Sigstrom Let al.The arginine-nitric oxide pathway in thrombotic microangiopathy. Scand J Urol Nephrol1997; 31: 477-479.
52.
Azuma H, Sato J, Hamasaki Het al.Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of L-arginine in regenerated endothelial cells. Br J Pharmacol1995; 115: 1001-1004.
53.
Usui M, Matsuoka H, Miyazaki Het al.Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci1998; 62: 2425-2430.
54.
Feng Q, Lu X, Fortin AJet al.Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure. Cardiovasc Res1998; 37: 667-675.
55.
Piatti P, Fragasso G, Monti LDet al.Acute intravenous L-arginine infusion decreases endothelin-1 levels and improves endothelial function in patients with angina pectoris and normal coronary arteriograms: correlation with asymmetric dimethylarginine levels. Circulation2003; 107: 429-436.
56.
Masuda H, Goto M, Tamaoki Set al.Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia. Br J Pharmacol1999; 126: 211-218.
57.
Abbasi F, Asagmi T, Cooke JPet al.Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol2001; 88: 1201-1203.
58.
Boger RH, Bode-Boger SM, Sydow Ket al.Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol2000; 20: 1557-1564.
59.
Boger RH, Lentz SR, Bode-Boger SMet al.Elevation of asymmetrical dimethylarginine may mediate endothelial dys-function during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Colch)2001; 100: 161-167.
60.
Yoo JH, Lee SC.Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis2001; 158: 425-430.
61.
Masuda H, Tsujii T, Okuno Tet al.Involvement of accumulated endogenous NOS inhibitors and decreased NOS activity in the impaired neurogenic relaxation of the rabbit proximal urethra with ischaemia. Br J Pharmacol2001; 133: 97-106.
62.
Hermenegildo C, Medina P, Peiro Met al.Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in hyperthyroid patients. J Clin Endocrinol Metab2002; 87: 5636-5640.
63.
Das I, Khan NS, Puri BKet al.Elevated endogenous nitric oxide synthase inhibitor in schizophrenic plasma may reflect abnormalities in brain nitric oxide production. Neurosci Lett1996; 215: 209-211.
64.
Rawal N, Lee YJ, Whitaker JNet al.Urinary excretion of NG-dimethylarginines in multiple sclerosis patients: preliminary observations. J Neurol Sci1995; 129: 186-191.
65.
Inoue R, Miyake M, Kanazawa Aet al.Decrease of 3-methyl-histidine and increase of NG, NG-dimethylarginine in the urine of patients with muscular dystrophy. Metabolism1979; 28: 801-804.
66.
Fandriks L, von Bothmer C, Johansson Bet al.Water extract of Helicobacter pylori inhibits duodenal mucosal alkaline secretion in anesthetized rats. Gastroenterology1997; 113: 1570-1575.
